-
Tytuł:
-
A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
-
Autorzy:
-
Koga T; a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.; b Center for Bioinformatics and Molecular Medicine , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Sumiyoshi R; a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Kawakami A; a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Yoshizaki K; c Department of Biomolecular Science and Regulation , The Institute of Scientific and Industrial Research, Osaka University , Osaka , Japan.
-
Źródło:
-
Modern rheumatology [Mod Rheumatol] 2019 Mar; Vol. 29 (2), pp. 302-305. Date of Electronic Publication: 2019 Jan 14.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2021- : Oxford : Oxford University Press
Original Publication: Tokyo, Japan : Spring-Verlag Tokyo, c2000-
-
MeSH Terms:
-
Castleman Disease*/diagnosis
Castleman Disease*/immunology
Castleman Disease*/therapy
Interleukin-6*/antagonists & inhibitors
Interleukin-6*/blood
Antibodies, Monoclonal, Humanized/*pharmacology
Glucocorticoids/*pharmacology
Antibodies/blood ; Herpesvirus 8, Human/immunology ; Humans ; Immunologic Factors/pharmacology ; Japan ; Prognosis ; Receptors, Interleukin-6/immunology ; Treatment Outcome
-
Contributed Indexing:
-
Keywords: Idiopathic multicentric Castleman's disease; interleukin-6; tocilizumab
-
Substance Nomenclature:
-
0 (Antibodies)
0 (Antibodies, Monoclonal, Humanized)
0 (Glucocorticoids)
0 (Immunologic Factors)
0 (Interleukin-6)
0 (Receptors, Interleukin-6)
I031V2H011 (tocilizumab)
-
SCR Disease Name:
-
Multi-centric Castleman's Disease
-
Entry Date(s):
-
Date Created: 20181005 Date Completed: 20190503 Latest Revision: 20220408
-
Update Code:
-
20240104
-
DOI:
-
10.1080/14397595.2018.1532383
-
PMID:
-
30285516
-
Castleman's disease (CD), a heterogeneous group of lymphoproliferative disorders, is divided into unicentric CD (UCD) and multicentric CD (MCD) based on the number of regions of enlarged lymph nodes with characteristic histopathologic features. The clinical pictures and treatment differ greatly between these UCD and MCD. In MCD, cases of human herpesvirus 8-negative patients with unknown etiology are defined as idiopathic MCD (iMCD). Most cases of UCD are treatable by surgical excision. The prognosis of iMCD varies, and it may be challenging to achieve remission. Glucocorticoids are initiated as the first choice for therapy, but for glucocorticoid-resistant cases, interleukin (IL)-6 inhibition is initiated. However, an IL-6 inhibitor is not effective for all iMCD cases, and refractory cases occur despite these treatments. In this review, we briefly summarize the role of IL-6 in iMCD, and we discuss the efficacy that has been reported for tocilizumab (TCZ), the anti-IL-6 receptor antibody, for patients with iMCD in Japan. Factors predicting the therapeutic response to IL-6 remain to be identified, and the verification of the long-term safety of IL-6 inhibition is needed.